TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00547495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 5 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 10 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
Study: NCT03668275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (partial) oncological home-hospitalization
Description: Patients assigned to oncological home-hospitalization will receive as many as possible parts of their oncological treatment at their homes. These include the required preparatory actions before treatment administration is possible and/or the treatment administration itself in case of subcutaneous cancer drugs.
Study: NCT01194466

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
Study: NCT02268253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp Injection
Description: Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.
Study: NCT01102049

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish, beef, fruit
Study: NCT02537769

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left ventricular assist device (LVAD)
Description: Left ventricular assist device placement (LVAD). All participants will receive an LVAD as a part of routine care for their advanced heart failure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left ventricular assist device (LVAD)
Description: Left ventricular assist device placement (LVAD). All participants will receive an LVAD as a part of routine care for their advanced heart failure.
Study: NCT02921919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol
Study: NCT02537769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tricuspid Valve Repair (TVR)
Description: Participants will be randomly assigned to receive a tricuspid valve repair (TVR) to repair their tricuspid valve regurgitation in addition to an LVAD placement. Only half of enrolled participants will receive this procedure.
Study: NCT00687076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard of medical care for PAD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard of medical care for PAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Daily dose of 325 mg of aspirin
Study: NCT01194466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
Study: NCT04470323

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry
Description: Lymphocyte subsets in peripheral blood were assessed by staining 50 µl of blood sample with 5 µl of Fluoroisothiocyanate (FITC)-conjugated- PD-1, phycoerythrin (PE)-conjugated-CD8, peridinium-chlorophyll-protein (Per-CP)-conjugated-CD4, Peridinium-chlorophyll-protein (Per-CP)-conjugated anti-CD3 and allophycocyanin (APC) conjugated anti-CD28.

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry
Description: Lymphocyte subsets in peripheral blood were assessed by staining 50 µl of blood sample with 5 µl of Fluoroisothiocyanate (FITC)-conjugated- PD-1, phycoerythrin (PE)-conjugated-CD8, peridinium-chlorophyll-protein (Per-CP)-conjugated-CD4, Peridinium-chlorophyll-protein (Per-CP)-conjugated anti-CD3 and allophycocyanin (APC) conjugated anti-CD28.
Study: NCT01206348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide
Description: Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night
Study: NCT04222439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI for the Diagnosis of Gastrointestinal Diseases
Description: After receiving standard preparation regimen, patients go through colonoscopy or gastroscopy under the AI monitoring device. The whole procedure is monitored by AI associated recognition system. Gastrointestinal diseases will be detect and diagnosis in which the AI device will automatically captured relevant images and report the site of each segment on the screen. Histology analysis is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
Study: NCT03848221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Complete
Description: Systane Complete is an artificial tear.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sensitive Eyes Rewetting Drops
Description: Sensitive Eyes Rewetting Drops is a rewetting drop.
Study: NCT04377594

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radio frequency ablation
Description: Two different radio frequency ablation procedures
Study: NCT06068699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postcard
Description: Participants received a postcard asking them to address non-adherence to remote monitoring.
Study: NCT01254019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2402968 6mg/kg/week
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2402968 6mg/kg/week
Description: subcutaneous
Study: NCT03504072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 mg,
Description: tofacitinib 5 mg 12 hourly daily for 9 months
Study: NCT00687076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Daily dose of 325 mg of aspirin
Study: NCT02268253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp Injection
Description: Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp Injection
Description: Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp Injection
Description: Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp Injection
Description: Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.
Study: NCT03504072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept 50 mg sc every 7 days interval in 1st month, every 15 days interval in 2nd month and then every 21 days interval from 3rd month onward upto 9 months
Study: NCT02035735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WL and NBI
Description: For each patient with a suspicion of squamous cell carcinoma of the oropharynx, hypopharynx or larynx for whom a laryngoscopy under general anesthesia (LGA) is expected benefit the day before a transnasal endoscopy with white lamp (WL) and NBI by two different operators. Suspected mucosal abnormalities showed by one or the two technics are reported in a table wich describes the different areas of the pharynx and the larynx. During the LGA, several biopsies are performed and identified (WL and/or NBI).
Study: NCT05015374

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin
Description: 350 mg/capsule (2mg Astaxanthin)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04142619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCARTCS1A
Description: Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor
Study: NCT01131962

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic control of hematemesis
Description: Endoscopy is performed to diagnose the cause of hematemesis and to control it using band ligation or sclerotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic control of hematemesis
Description: Endoscopy is performed to diagnose the cause of hematemesis and to control it using band ligation or sclerotherapy
Study: NCT00687076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Niaspan
Description: Daily dose of 1500 mg of placebo Niaspan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Ezetimibe
Description: Daily dose of 10 mg of placebo Ezetimibe

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Description: Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Description: Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.
Study: NCT01842659

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Methylation Index
Description: To calculate the methylation index (MI) of imprinted regions.
Study: NCT01203345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: The infants received their first dose of study drug within 24 hours of randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An equal volume of 5 percent albumin solution
Study: NCT01645176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine/Atorvastatin
Description: Hydroxychloroquine 200-600 mg /day Atorvastatin 40 mg/day
Study: NCT03206671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab window
Description: Rituximab window (375 mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab window
Description: Rituximab window (375 mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab window
Description: Rituximab window (375 mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab window
Description: Rituximab window (375 mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Additional doses of Rituximab
Description: 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle, 1 dose of rituximab before the start of the third chemotherapy cycle, 1 dose of Rituximab before the start of the forth chemotherapy cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: see detailed protocol description

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: see detailed protocol description

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: see detailed protocol description

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: see detailed protocol description

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin hydrochloride
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: see detailed protocol description
Study: NCT04419246

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interscalene block
Description: ultrasound guided ultrasound guided interscalene block 30 minutes before operation. 30 minutes before operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: 10 mg/kg intravenous tranexamic acid 10 minutes before the incision.
Study: NCT03061474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Oral Tablet
Study: NCT00781196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Description: capsule 0.5 mg once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsule, once a day
Study: NCT03516604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: PF-04995274 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet, identical to PF-04995274 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet, identical to PF-04995274 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo capsule, identical to citalopram capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsule, identical to citalopram capsule
Study: NCT02361437

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vasculera
Description: Vasculera 630 mg b.i.d.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vasculera
Description: Vasculera 630 mg b.i.d.
Study: NCT00842257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Panitumumab is administered intravenously (IV) by an infusion pump through a peripheral line or indwelling catheter using a 0.2 or 0.22-micron in-line filter infusion set-up over 1 hour 15 minutes. The starting panitumumab dose is 6 mg/kg administered every 14 days for as long as patients are on study without evidence of disease progression or demonstrating intolerance to treatment. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual body weight at each visit. Panitumumab will be diluted in a minimum of 100 mL of pyrogen-free 0.9% sodium chloride solution (normal saline solution, supplied by the site). The maximum concentration of the diluted solution to be infused should not exceed 10 mg/mL.
Study: NCT01795144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin 9-39
Description: OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin 9-39
Description: OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
Study: NCT03229707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital photography using software Photoshop
Description: When taking the image, a gray card is used for subsequent exposure calibration in Adobe Camera Raw (which is packaged with Photoshop).~* Images are then opened into Photoshop.~* The INFO panel must be open.~* Click on the small eyedropper in the Info panel window and click on ''Lab Color.~* Place the mouse over the center of the tooth to be measured for L value.~* Click on the HSB Color option, which stands for hue, saturation, and brightness.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vita 3D master shade guide
Description: Alpha (A)Perfectly matched Beta (B)Not perfectly matched Charlie (C)unacceptable Determent by 10 observers
Study: NCT03694288

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant removal
Description: Surgical Implant removal
Study: NCT03126812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC=6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 80 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg flat dose, starting cycle 2
Study: NCT03988569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: audiovisual decision aid
Description: Will view AVDA and then have opportunity for questions with physician before signing consent forms
Study: NCT03795428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemziviptadil (PB1046) Injection
Description: Once-weekly subcutaneous injection
Study: NCT04440046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy thoracic spine
Description: Manual therapy mobilization directed to the costovertebral joint.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy glenohumeral joint
Description: Manual therapy mobilization directed to the glenohumeral joint.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual therapy glenohumeral joint
Description: Manual therapy mobilization directed to the glenohumeral joint.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham thoracic manual therapy
Description: Sham manual therapy directed to the costovertebral joint.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham thoracic manual therapy
Description: Sham manual therapy directed to the costovertebral joint.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham glenohumeral manual therapy
Description: Sham manual therapy directed to the glenohumeral joint.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Therapeutic exercise program consisting on isometric exercise with progressive load.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Therapeutic exercise
Description: Therapeutic exercise program consisting on isometric exercise with progressive load.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Therapeutic exercise
Description: Therapeutic exercise program consisting on isometric exercise with progressive load.
Study: NCT04439799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Cypionate 200 Mg/ML
Description: Participants in this group will receive intramuscular testosterone cypionate injections of 1 cc (200mg) once every 14 days for four months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Testosterone
Description: Participant in this group will receive Intranasal testosterone administered using a multi-dose dispenser, as two or three daily doses (5.5 mg per nostril, 11.0 mg single dose) for 4 consecutive months,
Study: NCT00099619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide/insulin glargine
Description: Subcutaneously injected exenaide 10 mcg twice daily for 16 weeks; then insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine/exenatide
Description: Subcutaneously injected insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels; then exenaide 10 mcg twice daily for 16 weeks
Study: NCT01391130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2510924
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Administered orally
Study: NCT04108754

Intervention type: OTHER
Intervention: microangiopathic burden
Description: to determine the value of the global microangiopathic burden on the prediction of early stroke risk in a homogeneous cohort of TIA.
Study: NCT02274896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PD Catheter group
Description: PD catheter